Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308385280> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4308385280 abstract "<h3>Background</h3> STING agonists have been pursued as a strategy to trigger innate immune activation within the tumor microenvironment, which can lead to adaptive immunity and tumor regression in mice. However, clinically activity of STING agonists has been less impressive. We hypothesized that a low response rate clinically could be because most patients have non-T cell-inflamed (cold) tumors. We hypothesized that non-T cell-inflamed tumors may lack the required CD103<sup>+</sup>dendritic cell (DC) subset for T cell priming, thus failing to make the bridge to adaptive immunity. To investigate this notion, we turned to a B-catenin-driven genetically engineered mouse melanoma model, which is non-inflamed and known to lack CD103<sup>+</sup> DCs. We evaluated whether recruitment of CD103<sup>+</sup> DCs via Flt3L might cooperate with a STING agonist to promote tumor control, alone or in combination with checkpoint blockade antibodies. <h3>Methods</h3> We used the BRAF-activated, PTEN-deleted, B-catenin-stabilized (BPC) genetic melanoma model. Our laboratory previously showed that these tumors lack spontaneous CD103<sup>+</sup> DC and T cell infiltration and have low expression of the chemokines known to recruit these cells, which closely resembles the biology of many non-T cell-inflamed human cancers. To recruit and activate CD103<sup>+</sup> DCs to these tumors, we injected intratumoral Flt3L alone, the STING agonist DMXAA alone, and both in combination. <h3>Results</h3> Intratumoral DMXAA injection led to significant increases in CD8<sup>+</sup> T cells in BPC tumors five days post injection. However, the CD103<sup>+</sup> DC numbers in these tumors were not increased. Moreover, T cells recruited following DMXAA treatment were unable to control tumors alone or with anti-PD-L1 + anti-CTLA-4. This led us to adopt an additional strategy aimed at promoting CD103<sup>+</sup> DC accumulation directly. A single injection of Flt3L was able to drive CD103<sup>+</sup> DC accumulation in BPC tumors. However, Flt3L alone or with a subsequent DMXAA injection had minimal effects on tumor growth. Excitingly, Flt3L and DMXAA injection followed by anti-PD-L1 + anti-CTLA-4 mAB therapy led to significant tumor control. <h3>Conclusions</h3> Injection of Flt3L + DMXAA supported intratumoral accumulation of both CD8<sup>+</sup> T cells and CD103<sup>+</sup> DCs. This enabled subsequent therapeutic activity of anti-CTLA-4 + anti-PD-L1 mAb therapy in this very challenging cold tumor model. Inasmuch as tumors in this model fail to respond to vaccination, adoptive T cell therapy, and checkpoint blockade strategies, the activity of this regimen is highly significant. Clinical investigation of intratumoral Flt3L + STING agonists should be prioritized for future study in anti-PD-1-refractory patients. <h3>Ethics Approval</h3> This study obtained ethics approval by the Institutional Animal Care and Use Committee (IACUC) at the University of Chicago as outlined in the animal protocol #71621. The IBC protocol number is IBC1309(3)." @default.
- W4308385280 created "2022-11-11" @default.
- W4308385280 creator A5057828787 @default.
- W4308385280 creator A5085317448 @default.
- W4308385280 date "2022-11-01" @default.
- W4308385280 modified "2023-09-25" @default.
- W4308385280 title "828 Combination of Flt3L and STING agonism sensitizes non-T cell-inflamed tumors to checkpoint blockade therapy" @default.
- W4308385280 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0828" @default.
- W4308385280 hasPublicationYear "2022" @default.
- W4308385280 type Work @default.
- W4308385280 citedByCount "0" @default.
- W4308385280 crossrefType "proceedings-article" @default.
- W4308385280 hasAuthorship W4308385280A5057828787 @default.
- W4308385280 hasAuthorship W4308385280A5085317448 @default.
- W4308385280 hasBestOaLocation W43083852801 @default.
- W4308385280 hasConcept C100701293 @default.
- W4308385280 hasConcept C126322002 @default.
- W4308385280 hasConcept C127413603 @default.
- W4308385280 hasConcept C13373296 @default.
- W4308385280 hasConcept C146978453 @default.
- W4308385280 hasConcept C167672396 @default.
- W4308385280 hasConcept C170493617 @default.
- W4308385280 hasConcept C203014093 @default.
- W4308385280 hasConcept C2776090121 @default.
- W4308385280 hasConcept C2776107976 @default.
- W4308385280 hasConcept C2777658100 @default.
- W4308385280 hasConcept C2777701055 @default.
- W4308385280 hasConcept C2778170410 @default.
- W4308385280 hasConcept C2778468042 @default.
- W4308385280 hasConcept C2779300339 @default.
- W4308385280 hasConcept C502942594 @default.
- W4308385280 hasConcept C59822182 @default.
- W4308385280 hasConcept C71924100 @default.
- W4308385280 hasConcept C81444415 @default.
- W4308385280 hasConcept C86803240 @default.
- W4308385280 hasConcept C8891405 @default.
- W4308385280 hasConceptScore W4308385280C100701293 @default.
- W4308385280 hasConceptScore W4308385280C126322002 @default.
- W4308385280 hasConceptScore W4308385280C127413603 @default.
- W4308385280 hasConceptScore W4308385280C13373296 @default.
- W4308385280 hasConceptScore W4308385280C146978453 @default.
- W4308385280 hasConceptScore W4308385280C167672396 @default.
- W4308385280 hasConceptScore W4308385280C170493617 @default.
- W4308385280 hasConceptScore W4308385280C203014093 @default.
- W4308385280 hasConceptScore W4308385280C2776090121 @default.
- W4308385280 hasConceptScore W4308385280C2776107976 @default.
- W4308385280 hasConceptScore W4308385280C2777658100 @default.
- W4308385280 hasConceptScore W4308385280C2777701055 @default.
- W4308385280 hasConceptScore W4308385280C2778170410 @default.
- W4308385280 hasConceptScore W4308385280C2778468042 @default.
- W4308385280 hasConceptScore W4308385280C2779300339 @default.
- W4308385280 hasConceptScore W4308385280C502942594 @default.
- W4308385280 hasConceptScore W4308385280C59822182 @default.
- W4308385280 hasConceptScore W4308385280C71924100 @default.
- W4308385280 hasConceptScore W4308385280C81444415 @default.
- W4308385280 hasConceptScore W4308385280C86803240 @default.
- W4308385280 hasConceptScore W4308385280C8891405 @default.
- W4308385280 hasLocation W43083852801 @default.
- W4308385280 hasOpenAccess W4308385280 @default.
- W4308385280 hasPrimaryLocation W43083852801 @default.
- W4308385280 hasRelatedWork W1930328534 @default.
- W4308385280 hasRelatedWork W1981274926 @default.
- W4308385280 hasRelatedWork W2387430262 @default.
- W4308385280 hasRelatedWork W2904909612 @default.
- W4308385280 hasRelatedWork W3158438576 @default.
- W4308385280 hasRelatedWork W3177607563 @default.
- W4308385280 hasRelatedWork W4291378227 @default.
- W4308385280 hasRelatedWork W4304979265 @default.
- W4308385280 hasRelatedWork W4312075079 @default.
- W4308385280 hasRelatedWork W4366185366 @default.
- W4308385280 isParatext "false" @default.
- W4308385280 isRetracted "false" @default.
- W4308385280 workType "article" @default.